MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer.
Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision has emerged as the standard treatment for locally advanced rectal cancer (LARC) patients. However, many cases do not respond to neoadjuvant CRT, suffering unnecessary toxicities and surgery delays. Thus, identification of predictive biomarkers for neoadjuvant CRT is a current clinical need. In the present study, microRNA-31 expression was measured in formalin-fixed paraffin-embedded (FFPE) biopsies from 78 patients diagnosed with LARC who were treated with neoadjuvant CRT. Then, the obtained results were correlated with clinical and pathological characteristics and outcome. High microRNA-31 (miR-31) levels were found overexpressed in 34.2% of cases. Its overexpression significantly predicted poor pathological response (p = 0.018) and worse overall survival (OS) (p = 0.008). The odds ratio for no pathological response among patients with miR-31 overexpression was 0.18 (Confidence Interval = 0.06 to 0.57; p = 0.003). Multivariate analysis corroborated the clinical impact of miR-31 in determining pathological response to neoadjuvant CRT as well as OS. Altogether, miR-31 quantification emerges as a novel valuable clinical tool to predict both pathological response and outcome in LARC patients.
Medical Oncology Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. ccarames@fjd.es.
Cristina
C
Caramés
Traslational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. ion.cristobal@fjd.es.
Ion
I
Cristobal
Medical Oncology Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. victor.moreno@fjd.es.
Víctor
V
Moreno
Radiation Oncology Department, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. marin5si@yahoo.com.
Juan P
JP
Marín
Pathology Department, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. paula.galonso@fjd.es.
Paula
P
González-Alonso
Traslational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. blanca.torrejon@quironsalud.es.
Blanca
B
Torrejón
Department of Genetics and Genomics, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. pablo.minguez@quironsalud.es.
Pablo
P
Minguez
Medical Oncology Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. Aleon@fjd.es.
Ana
A
Leon
Medical Oncology Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. JIMartin@fjd.es.
José I
JI
Martín
Medical Oncology Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. rhernandezl@quironsalud.es.
Roberto
R
Hernández
Medical Oncology Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. manuel.pedregal@quironsalud.es.
Manuel
M
Pedregal
Gastroenterology Department, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. MJMartin@fjd.es.
María J
MJ
Martín
Surgery Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. DCORTES@fjd.es.
Delia
D
Cortés
Surgery Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. Damian.garcia@uam.es.
Damian
D
García-Olmo
Pathology Department, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. mgg10167@gmail.com.
María J
MJ
Fernández
Pathology Department, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. frojo@fjd.es.
Federico
F
Rojo
Medical Oncology Department, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. jesus.garciafoncillas@oncohealth.eu.|Traslational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundaci&#243;n Jim&#233;nez D&#237;az, Avda. Reyes Cat&#243;licos-2, 28040 Madrid, Spain. jesus.garciafoncillas@oncohealth.eu.
Jesús
J
García-Foncillas
D000328:Adult; D000368:Aged; D015415:Biomarkers; D059248:Chemoradiotherapy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D012004:Rectal Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016896:Treatment Outcome
D015415:Biomarkers; C534612:MIRN31 microRNA, human; D035683:MicroRNAs
miR-31; neoadjuvant chemoradiotherapy; prognosis; rectal cancer